Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003Advancing two lead product candidates in Phase 1/2 clinical trials Additional...
Reports
- IPO raised an aggregate of approximately $149.1 million in gross proceeds- Strong cash position of $198.6 million to be...
Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK® Net Product Revenues of $8.0 MillionRevised Commercial Strategy and Operating Plan...
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data...
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Retail Opportunity Investments Corp. (NASDAQ:ROIC) announced today financial and operating results for...
Phase 3 randomized withdrawal trial for cardiomyopathy in Barth plannedReCLAIM Phase 1 data presented at ARVO 2021 supports ReCLAIM-2 Phase...
- Continued execution on strategy to build the most comprehensive national solar network and portfolio of renewable energy solutions to...
Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted TherapeuticsDENVER, May 18,...
Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated...
Dun & Bradstreet Holdings, Inc. (NYSE: DNB), a leading global provider of business decisioning data and analytics, today announced unaudited...
